On July 28, Johnson & Johnson rose 3.16% in regular trading, trading at $272.77/share, with turnover of $623 million.

On the news front, Johnson & Johnson announced it will pay up to $5.5 billion to settle approximately 76,000 lawsuits alleging its talc products caused ovarian cancer, aiming to bring finality to litigation spanning fifteen years. The first payment is capped at $3 billion in 2027, with no additional payments required before 2028. The deal is conditioned on approval from law firms representing at least 95% of remaining claimants in state and federal courts. The company continues to deny its talc products are carcinogenic, citing scientific research supporting product safety.

Multiple catalysts converged to boost sentiment. Johnson & Johnson's OTTAVA robotic surgical system recently received FDA De Novo authorization as a table-integrated soft tissue surgical robot, approved for ten upper abdominal general surgery indications. Additionally, Q2 results exceeded expectations with adjusted EPS of $2.90, and the company raised its full-year adjusted EPS guidance midpoint to $11.68, above the consensus estimate of $11.58.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)